Cidara near­ly dou­bles in val­ue as an­tivi­ral bi­o­log­ic pre­vents flu in mid-stage tri­al

Cidara Ther­a­peu­tics’ long-act­ing an­tivi­ral bi­o­log­ic ef­fec­tive­ly pre­vent­ed sea­son­al flu in­fec­tions in a mid-stage tri­al, the biotech said Mon­day. Its shares …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER